Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Expression Models Predicting Survival in DLBCL Treated With R-CHOP
NCT00450385Phase 2Terminated
- Sponsor
- University of Miami
- Start
- Apr 2007
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Miami. Started Apr 2007; status: terminated.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00450385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450385.